Susceptibility of Rat Steatotic Liver to Ischemia-Reperfusion Is Treatable With Liver-Selective Matrix Metalloproteinase Inhibition
Overview
Authors
Affiliations
Background And Aims: This study examined whether enhanced susceptibility of steatotic liver to ischemia-reperfusion (I/R) injury is due to impaired recruitment of bone marrow (BM) progenitors of liver sinusoidal endothelial cells (LSECs, also called sinusoidal endothelial cell progenitor cells [sprocs]) with diminished repair of injured LSECs and whether restoring signaling to recruit BM sprocs reduces I/R injury.
Approach And Results: Hepatic vessels were clamped for 1 hour in rats fed a high-fat, high-fructose (HFHF) diet for 5, 10, or 15 weeks. Matrix metalloproteinase 9 (MMP-9) antisense oligonucleotides (ASO) or an MMP inhibitor were used to induce liver-selective MMP-9 inhibition. HFHF rats had mild, moderate, and severe steatosis, respectively, at 5, 10, and 15 weeks. I/R injury was enhanced in HFHF rats; this was accompanied by complete absence of hepatic vascular endothelial growth factor (VEGF)-stromal cell-derived factor 1 (sdf1) signaling, leading to lack of BM sproc recruitment. Liver-selective MMP-9 inhibition to protect against proteolytic cleavage of hepatic VEGF using either MMP-9 ASO or intraportal MMP inhibitor in 5-week and 10-week HFHF rats enhanced hepatic VEGF-sdf1 signaling, increased BM sproc recruitment, and reduced alanine aminotransferase (ALT) by 92% and 77% at 5 weeks and by 80% and 64% at 10 weeks of the HFHF diet, respectively. After I/R injury in 15-week HFHF rats, the MMP inhibitor reduced active MMP-9 expression by 97%, ameliorated histologic evidence of injury, and reduced ALT by 58%, which is comparable to control rats sustaining I/R injury. Rescue therapy with intraportal MMP inhibitor, given after ischemia, in the 5-week HFHF rat reduced ALT by 71% and reduced necrosis.
Conclusions: Lack of signaling to recruit BM sprocs that repair injured LSECs renders steatotic liver more susceptible to I/R injury. Liver-selective MMP-9 inhibition enhances VEGF-sdf1 signaling and recruitment of BM sprocs, which markedly protects against I/R injury, even in severely steatotic rats.
Xu M, Alwahsh S, Kim M, Kollmar O Transpl Int. 2024; 37:13557.
PMID: 39726675 PMC: 11671227. DOI: 10.3389/ti.2024.13557.
Liu J, Luo R, Zhang Y, Li X Clin Mol Hepatol. 2024; 30(4):585-619.
PMID: 38946464 PMC: 11540405. DOI: 10.3350/cmh.2024.0222.
Qing Z, Luo Q, Duan J, Lin J, Huang H, Yang S Mol Med Rep. 2024; 29(4).
PMID: 38426545 PMC: 10926105. DOI: 10.3892/mmr.2024.13188.
Mesenchymal stem cells and ferroptosis: Clinical opportunities and challenges.
Cui M, Chen F, Shao L, Wei C, Zhang W, Sun W Heliyon. 2024; 10(3):e25251.
PMID: 38356500 PMC: 10864896. DOI: 10.1016/j.heliyon.2024.e25251.
Ferroptosis: a promising candidate for exosome-mediated regulation in different diseases.
Liu L, Ye Y, Lin R, Liu T, Wang S, Feng Z Cell Commun Signal. 2024; 22(1):6.
PMID: 38166927 PMC: 11057189. DOI: 10.1186/s12964-023-01369-w.